Data Insights

CHM-1101 by Chimeric Therapeutics for Astrocytoma: Likelihood of Approval

CHM-1101 is under clinical development by Chimeric Therapeutics and currently in Phase I for Astrocytoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-1101 in Astrocytoma

Data Insights

CHM-1101 by Chimeric Therapeutics for Malignant Glioma: Likelihood of Approval

CHM-1101 is under clinical development by Chimeric Therapeutics and currently in Phase I for Malignant Glioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-1101 in Malignant Glioma

Data Insights

CHM-0201 by Chimeric Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

CHM-0201 is under clinical development by Chimeric Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-0201 in Myelodysplastic Syndrome

Data Insights

CHM-2101 by Chimeric Therapeutics for Colorectal Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Colorectal Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Colon Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Colon Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Colon Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Pancreatic Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Pancreatic Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Gastric Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Gastric Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Rectal Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Rectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Rectal Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Neuroendocrine Tumors: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Neuroendocrine Tumors

Data Insights

CHM-1101 by Chimeric Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

CHM-1101 is under clinical development by Chimeric Therapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-1101 in Recurrent Glioblastoma Multiforme (GBM)